Nasal cavity and paranasal sinus carcinoma

Summary

Nasal cavity and paranasal sinus carcinoma (MONDO:0056819) is a cancer and 17 clinical trials. Top therapeutic interventions include cisplatin, tazemetostat, and becotatug vedotin. A subtype of head and neck carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 17

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	nasal cavity and paranasal sinus carcinoma
Mondo ID	MONDO:0056819
NCIT	C54293
UMLS	C1710095
MedGen	328032
GARD	0007650
Is cancer (heuristic)	yes

Also known as: nasal cavity and paranasal sinus cancer · nasal cavity and paranasal sinus carcinoma · paranasal sinus and nasal cavity cancer · sinonasal carcinoma

Disease family

This is a subtype of head and neck carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › head and neck carcinoma › nasal cavity and paranasal sinus carcinoma

Related subtypes (15): eye carcinoma, external ear carcinoma, middle ear carcinoma, nasal cavity carcinoma, growth hormone-producing pituitary gland carcinoma, hypopharyngeal carcinoma, ameloblastic carcinoma, laryngeal small cell carcinoma, pharyngeal adenoid cystic carcinoma, head and neck squamous cell carcinoma, nasopharyngeal carcinoma, pituitary adenocarcinoma, carcinoma of floor of mouth, lip and oral cavity carcinoma, oropharyngeal carcinoma

Subtypes (2): paranasal sinus carcinoma, nasal cavity and paranasal sinus squamous cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 17.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	9
PHASE2	6
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00707473	PHASE2	ACTIVE_NOT_RECRUITING	Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer
NCT05151588	PHASE2	NOT_YET_RECRUITING	Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma
NCT07320508	PHASE2	RECRUITING	Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study
NCT07522879	PHASE2	RECRUITING	A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma
NCT01469429	PHASE1/PHASE2	COMPLETED	Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
NCT01806675	PHASE1/PHASE2	COMPLETED	18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
NCT03082534	PHASE2	COMPLETED	Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
NCT04162873	PHASE2	TERMINATED	Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
NCT04755855	Not specified	RECRUITING	Prospective Sinonasal Cancer Multi-institution Study
NCT05483374	Not specified	RECRUITING	The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
NCT07512466	Not specified	NOT_YET_RECRUITING	Evaluation of Endoscopic Management of Sinonasal Tumors In Difficult Anatomical Locations
NCT07563088	Not specified	NOT_YET_RECRUITING	SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma
NCT01586767	Not specified	UNKNOWN	Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy
NCT03874455	Not specified	NO_LONGER_AVAILABLE	Tazemetostat Expanded Access Program for Adults With Solid Tumors
NCT03942380	Not specified	UNKNOWN	Cell-free Tumor DNA in Head and Neck Cancer Patients
NCT04788264	Not specified	COMPLETED	Exercise Training and Behavioral Modification for the Improvement of Physical Activity in Head and Neck Cancer Patients Undergoing Cancer Treatment
NCT04979000	Not specified	COMPLETED	HPV in Sinonasal Ca: Retrospective Analysis Association of Human Papilloma Virus (HPV) Serology and Behavioral Risk Factors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	2
TAZEMETOSTAT	4	2
BECOTATUG VEDOTIN	3	1
CHEMBL5398431	0	2